biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Consequences of a "no" vote: from IR

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 18, 2023 1:55pm

89 Views

Post# 35231126

RE:RE:RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR

Yep, maybe she wouldn't take the chance. But everything she did and didn't do can be discussed in terms of conflict of interest.

It's plausable enough to write a book about it, fiction or nonfiction. Cresence, xB3-001, corporate presentations, the Ellipses leak, all of it can be interpreted either way. I've never seen anything in all of Bioasis's documents that proves or disproves almost any scenario.

jd

<< Previous

Bullboard Posts

Next >>

Cannabix advances marijuana breathalyzer tech